Related trials
		 
			
				 
				
					ROADMAP, 2010 - olmesartan  vs placebo
				
			 
			
				 
				
					ADVANCE, 2007 - perindopril and indapamide  vs placebo
				
			 
			
				 
				
					LIFE (diabetic subgroup), 2002 - losartan  vs atenolol
				
			 
			
				 
				
					ALLHAT (lisi vs chlor, diabetic subgroup), 2002 - lisinopril  vs chlorthalidone
				
			 
			
				 
				
					IDNT irbesartan, 2001 - Irbesartan  vs placebo
				
			 
			
				 
				
					IPDM, 2001 - irbesartan  vs placebo
				
			 
			
				 
				
					RENAAL, 2001 - losartan  vs placebo
				
			 
			
				 
				
					IDNT (irbesartan vs amlodipine), 2001 - Irbesartan  vs amlodipine
				
			 
			
				 
				
					STOP-2 ACEI (diabetic subgroup), 2000 - ACE inhibitor  vs diuretic or beta-blocker
				
			 
			
				 
				
					STOP-2 (ACEI vs CCB) (diabetic subgroup), 2000 - ACE inhibitor  vs CCB
				
			 
			
				 
				
					HOPE (diabetic subgroup), 2000 - ACE inhibitor  vs placebo
				
			 
			
				 
				
					CAPP (diabetic subgroup), 1999 - captopril  vs diuretic or beta-blocker
				
			 
			
				 
				
					UKPDS 38, 1998 - captopril or atenolol  vs control
				
			 
			
				 
				
					UKPDS 39, 1998 - captopril  vs atenolol
				
			 
			
				 
				
					ORIENT,  - olmesartan  vs placebo
				
			 
		 
		 
		 
		
		See also:
		 
			
				
					All diabetes clinical trials
				
			
		
			
			All clinical trials of anti hypertensive agent 
			
		
		
			
			All clinical trials of perindopril and indapamide 
			
		
	 | 
	
		 
	 | 
	
	Treatments
	
	
		| Studied treatment | 
		
		fixed combination of perindopril and indapamide
		 
		
		
		 | 
	 
	
		| Control treatment | 
		
		placebo
		 
		
		
		 | 
	 
		
			| Concomittant treatment | 
			current therapy | 
		 
	 
	
	
	
	Patients
	
		
			| Patients | 
			patients with type 2 diabetes  irrespective of initial blood pressure levels or the use of other blood pressure lowering drugs | 
		 
	 
	
	
	
	
	
	
	Method and design
	
	
		| Randomized effectives | 
		NA / NA (studied vs. control) | 
	 
		
			| Primary endpoint | 
			composites of major macrovascular and microvascular events | 
		 
	
	 
	
	
	
	
	
	
	
  
	Results	
	
		
			No results available for this trial
			 - no clinical endpoint reported 
		 
Meta-analysis of all similar trials: 
			
				
					angiotensin renin system blockade in diabetes for all type of patients
				
			 
			
				
					angiotensin-receptor blockers in diabetes for all type of patients
				
			 
			
				
					anti hypertensive agent in diabetes for patients with or without hypertension
				
			 
	
  
	
	
	
	
	
	
	
	
	
	
	
		 
		Reference(s)
	
	
	
			- 
				
			    . 
			    Rationale and design of the ADVANCE study: a randomised trial of blood pressure lowering and intensive glucose control in high-risk individuals with type 2 diabetes mellitus. Action in Diabetes and Vascular Disease: PreterAx and DiamicroN Modified-Release Controlled Evaluation..
			    J Hypertens Suppl 2001 Nov;19:S21-8
			    
 
				
					 
					Pubmed
				 	
				|
				
					Hubmed
				
				| Fulltext
		 
		
			- 
				
			    Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, Harrap S, Poulter N, Marre M, Cooper M, Glasziou P, Grobbee DE, Hamet P, Heller S, Liu LS, Mancia G, Mogensen CE, Pan CY, Rodgers A, Williams B. 
			    Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial..
			    Lancet 2007 Sep 8;370:829-40
			    
 
				
					 
					Pubmed
				 	
				|
				
					Hubmed
				
				| Fulltext
		 
		
	 	
			 
			
			
			 
 |